NCT06004934View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

September 18, 2018

Study Completion Date

September 18, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

Avacopan

Administered orally.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Inc., Hialeah

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY